Matt Bresnahan will be speaking at the inaugural BioLogic Summit this January in San Diego. His session, "Developing and Implementing an Effective IP Strategy for AI/ML-Driven Biologics," will cover key topics like understanding IP rights, inventorship, and ownership of AI/ML-based inventions, along with strategies for protecting platform innovations and therapeutic modalities.  He will also review life cycle management strategy for a biologics therapeutic program and Freedom to Operate.

Presented by the experts behind PEGS and PepTalk, the BioLogic Summit is bringing the biologics community together to explore the game-changing potential of ML/AI in biopharmaceutical R&D.